Business
Omnicell Enhances Robotic IV Insourcing Offerings and Ramps up Investment in IV Automation Technology
Recent severe challenges in 503B supply creating need for novel, more reliable, and safer alternatives MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Omnicell,
About this update from Omnicell, Inc.
[{"type":"text","content":"\nRecent severe challenges in 503B supply creating need for novel, more reliable, and safer alternatives\n\n MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--\nOmnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced significant clinical enhancements and expansion of the Company’s unique IV compounding service, which combines advanced technology, clinical expertise, operational support, and workflow/analytics to address challenges in sterile compounding.\n\n\nThe complexities of IV compounding, including staffing, equipment, facilities, and regulations, have resulted in many hospitals choosing to outsource much of their sterile compounding operations. However, turmoil in outsourced compounding is leading to severe supply challenges and unpredictability, which can significantly impact patient care.1\n\n\nOmnicell’s IV compounding service is an emerging alternative to commercial outsourcing. Launched in 2016, the service has grown dramatically. To further enhance the service, the company has recently added expert pharmacist consultants, best practice operating models, and a library of scientific data including cGMP stability studies. These enhancements streamline adoption and optimize performance, facilitating better production planning and personnel staffing, establishing beyond-use-dating programs, and increasing the financial return to customers. Data shows that in-house compounding costs are 66 percent lower compared to outsourcing.2\n\n\n“Our recent experience with 503B outsourcing pharmacies has presented many challenges,” said Dennis Killian, PharmD, PhD, vice president of Clinical Operations, Peninsula Regional Medical Center. “Insourcing with Omnicell’s IV automation gives us control over inventory, quality, and drug spend, while helping us to achieve gains in sterile compounding efficiency and production.”\n\n\nWith disruption and uncertainty in the supply of compounded IV medications from outsourcers, Omnicell’s IV compounding service is one way the company partners with healthcare institutions to create an IV compounding strategy that helps to improve safety, drive down costs, facilitate compliance, and reduce dependency on the outsourcing supply base. This aligns with best practices from the Institute for Safe Medication Pract...